# A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

> **NCT06560645** · PHASE1 · TERMINATED · sponsor: **Prelude Therapeutics** · enrollment: 42 (actual)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Non-small Cell Lung Carcinoma
- SMARCA4 Mutation
- Esophageal Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Squamous Cell Carcinoma

## Interventions

- **DRUG:** PRT7732

## Key facts

- **NCT ID:** NCT06560645
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-04
- **Primary completion:** 2026-01-28
- **Final completion:** 2026-01-28
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06560645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06560645, "A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06560645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*